

TALKMED GROUP LIMITED

("TalkMed" or the "Company")

5th Annual General Meeting

24 April 2018



Disclaimer

This presentation contains certain financial information and results of operation, and may also contain certain projections, plans, strategies, and objectives of the Company which are not statements of historical fact but would constitute “forward-looking statements” that reflect the Company’s current views with respect to future events and financial performance. These views expressed herein are based on a number of estimates and current assumptions which are subject to business, economic and political uncertainties and contingencies, as well as various risks which are in many cases outside the control of the Company, and which may change over time and may cause the Company’s future results to be materially different than expected or indicated by such statements. No assurance can be given that future events will occur, that projections will be achieved, or that the Company’s assumptions are correct. Such forward-looking statements are not guarantees of future performance and accordingly, the actual results, financial condition, performance or achievements of the Company may differ materially from those anticipated by the Company in the forward-looking statements. The information contained herein is current only as of its date and shall not, under any circumstances, create any implication that such information is correct as of any time subsequent to the date hereof or that there has been no change in the financial condition or affairs of the Company since such date. Opinions expressed herein reflect the judgment of the Company as of the date of this presentation and may be subject to change. This presentation may be updated from time to time and there is no undertaking by the Company to post any such amendments or supplements to this presentation. The Company will not be responsible for any consequences resulting from the use of this presentation, nor any undue reliance placed upon any opinion or statement contained herein.



Agenda

- **Financial performance**
- Business and corporate update
- Summary and outlook




Performance review for the Group⁽¹⁾

For the year ended	31 Dec 2017 ("FY2017") S\$'000	31 Dec 2016 ("FY2016") S\$'000	% Increase/ (decrease)
Revenue	61,361	68,913	(11.0%)
Other income	883	908	(2.8%)
Total expenses	21,878	20,701	5.7%
Share of loss of associate	1,828	3,632	(49.7%)
Profit before tax	38,538	45,488	(15.3%)
Income tax expense	7,341	8,607	(14.7%)
Profit after tax ("PAT")	31,197	36,881	(15.4%)

⁽¹⁾ Defined as the Company, its subsidiaries and associate company




Revenue Breakdown – FY2017 vs FY2016




* Dr Ang was suspended from 25 Jul 2017


Market Capitalisation



Dividends Paid as a % of PAT



Hong Kong Integrated Oncology Centre Holdings Limited (“HKH”) – Revenue/ Loss/ TalkMed’s share of losses



⁽¹⁾ For the period from 22 September 2014 to 31 December 2015

⁽²⁾ On 9 June 2015, TalkMed entered into a collaboration agreement in relation to the investment in HKH and accordingly, took up the losses in HKH for the period from 9 June to 31 December 2015



Agenda

- Financial performance
- **Business and corporate update**
- Summary and Outlook



Business and corporate updates - *Key developments*

2017

Mar

- Stem Med Pte. Ltd. (“**Stem Med**”), a subsidiary of the Company, incorporated Stem Med Indonesia Pte. Ltd. (“**SMI**”)*, a 90%-owned subsidiary.
- SMI will be used to explore opportunities with respect to:
 - i. operation of cellular laboratories and storage facilities; and
 - ii. possible operation of cellular therapeutics clinics in Indonesia.

May

- The Company allotted and issued 657,143,000 Bonus Shares (as defined in the relevant announcements), bringing the total number of issued shares to 1,314,286,000 shares.
- TalkMed granted 3.8m share options and 512,335 performance shares to certain employees of the Group which represent 0.29% and 0.04% of the total issued shares respectively on the date that the options and awards are granted.

Sept

- TalkMed China Pte. Ltd. (“**TalkMed China**”)*, a wholly-owned subsidiary, was incorporated to explore healthcare-related collaborations in China.
- TalkMed China incorporated a 75%-owned subsidiary, TalkMed Chongqing Pte. Ltd.*, with the aim of providing healthcare management services in Chongqing.

**Not expected to have a material impact on the Group’s revenue and earnings in 2018.*



Business and corporate updates - *Key developments (cont'd)*

2017

2018

Oct

Nov

Mar

- Stem Med incorporated a 60%-owned subsidiary, DrSG Cellular Wellness Pte. Ltd.*, with A DrBrand Pte. Ltd. (“ADB”) taking the remaining 40%.
- ADB is the brand owner of DrGL®, DrSpa® and DrHair®. It has over 28 years of experience and research in the areas of skin care and hair care.
- This joint venture will customise solutions using protein-rich derivatives for skin care and hair rejuvenation.
- TalkMed China entered into a collaboration* with Beijing New Hope Hospital Management Co. Ltd. for TalkMed China to offer management services for the “Singapore Cancer Centre” branded oncology services in China.
- Our Group Chief Executive Officer, Dr Ang Peng Tiam resumed his medical duties.

**Not expected to have a material impact on the Group’s revenue and earnings in 2018.*



Agenda

- Financial performance
- Business and corporate update
- **Summary and outlook**



Summary and outlook

- Group revenue and PAT declined largely due to Dr Ang's 8-month suspension.
- Revenue and PAT declined by 11.0% and 15.4% respectively. The Company proposes a final dividend of S\$0.0137 per share. Together with the interim dividend of S\$0.00761 per share that was paid in August 2017, this will constitute 87.4% of the net profits attributable to owners of the Company in FY17.
- In 2018, the Company continues to explore M&A opportunities and/ or new collaborations.
- Dr Ang resumed medical duties on 25 March 2018 and we look forward to his contributions to the Group's revenue and earnings.



Thank you

